Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies

Journal of Interferon and Cytokine Research

Volumn 35, Issue 8, 2015, Pages 621-633

  Taylor, Joshua S ^a   Zhang, Qingling ^a   Julander, Justin G ^b   Stoycheva, Antitsa D ^a   Tan, Hua ^a   Moy, Christabel V ^a   Chanda, Sushmita ^a   Symons, Julian A ^a   Beigelman, Leonid N ^a   Blatt, Lawrence M ^a   Hong, Jin ^a  

^a AliosBiopharma   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 INTERFERON; ANTIVIRUS AGENT; CONSENSUS INTERFERON; HYPERGLYCOSYLATED INTERFERON ALFACON 1; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG; ALPHA INTERFERON; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC HEPATITIS B; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENCY; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; FRACTIONATION; GLYCOSYLATION; HAMSTER MODEL; HEPATITIS C; HEPATITIS C VIRUS; MALE; MOLECULAR CLONING; MOUSE; MUTAGENESIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PURIFICATION; RAT; REPLICON; SINGLE DRUG DOSE; SYRIAN HAMSTER; TRANSIENT TRANSFECTION; YELLOW FEVER; YELLOW FEVER VIRUS; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG MONITORING; GENETICS; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN CONFORMATION;

CRICETINAE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; RATTUS; YELLOW FEVER VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DRUG DESIGN; DRUG MONITORING; GLYCOSYLATION; HUMANS; INTERFERON-ALPHA; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; RECOMBINANT PROTEINS;

EID: 84938900160     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0138     Document Type: Article

References (30)

1. Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. 2007. Interferon therapy for chronic hepatitis B. Clin Liver Dis 11(4):839-849.
2. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. 2001. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12(2):195-202.
3. Bano-Polo M, Baldin F, Tamborero S, Marti-Renom MA, Mingarro I. 2011. N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon. Protein Sci 20(1):179-186.
4. Bartenschlager R, Kaul A, Sparacio S. 2003. Replication of the hepatitis C virus in cell culture. Antiviral Res 60(2):91-102.
5. Bukh J. 2004. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39(6):1469-1475.
6. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. 2008. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie 90(3):437-449.
7. Conradt HS, Egge H, Peter-Katalinic J, Reiser W, Siklosi T, Schaper K. 1987. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. J Biol Chem 262(30):14600-14605.
8. Elliot S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21(4):414-421.
9. Enomoto M, Tamori A, Murakami Y, Kawada N. 2014. Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents. Hepatol Res 44(4): 371-376.
10. Erickson AK, Seiwert S, Gale Jr., M. 2008. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha-2a and pegylated interferon-alpha-2b against hepatitis C virus infection. Antivir Ther 13(7):851-862.
11. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert Jr., DG, Witt K, Blatt LM. 1998. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 27(4):1136-1143.
12. Julander JG, Morrey JD, Blatt LM, Schafer K, Sidwell RW. 2007. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on Yellow fever virus infection in a hamster model. Antiviral Res 73(2):140-146.
13. Klein J, Lobel L, Pollak S, Lustbader B, Ogden RT, Sauer MV, Lustbader JW. 2003. Development and characterization of a long-acting recombinant hFSH agonist. Hum Reprod 18(1): 50-56.
14. Kozlowski A, Charles SA, Harris JM. 2001. Development of pegylated interferons for the treatment of chronic hepatitis C. Bio Drugs 15(7):419-429.
15. Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, Lambiase LR, Dickson RC, Weisner RH, Fiscella M, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM. 2009. Safety and antiviral activity of Albinterferon Alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 7(2):212-218.
16. Nyman TA, Kalkkinen N, Tolo H, Helin J. 1998. Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon-alpha2b and interferon-alpha14c produced by Sendai-virus-induced human peripheral blood leukocytes. Eur J Biochem 253(2):485-493.
17. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JXH, Garcia A, Moody G, Zaritskaya LS, Sung C. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303(2):540-548.
18. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. 1992. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killerinducing activities. J Interferon Res 12(1):55-59.
19. Pedder SC. 2003. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis 23 (Suppl 1): 19-22.
20. Pepinsky RB, Lepage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P. 2001. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297(3):1059-1066.
21. Perry CM, Jarvis B. 2001. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 61(15):2263-2288.
22. Pestka S. 2007. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282(28):20047-20051.
23. Quadt-Akabayov SR, Chill JH, Levy R, Kessler R, Anglister J. 2006. Determination of the human type I interferon receptor binding site on human interferon-a2 by cross saturation and an NMR-based model of the complex. Protein Sci 15(11): 2656-2668.
24. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferonbeta (IFN-beta). Pharm Res 15(4):641-649.
25. Sarasin-Filipowicz M, Wang X, Yan M, Duong FHT, Poli V, Hilton DJ, Zhang DE, Heim MH. 2009. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29(17):4841-4851.
26. Shakin-Eshleman SH, Spitalnik SL, Kasturi L. 1996. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J Biol Chem 271(11):6363-6366.
27. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. 2004. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 8(39):iii-iv, 1-125.
28. Utsumi J, Matsuo-Ogawa E, Nagahata T, Kasama K, Kagawa Y, Satoh Y. 1995. Carbohydrate-dependent biological activities of glycosylated human interferon-β on human hepatoblastoma cells in vitro. Microbiol Immunol 39(1):81-86.
29. Zaworski PG, Gill GS. 1988. Precipitation and recovery of proteins from culture supernatants using zinc. Anal Biochem 173(2):440-444.
30. Zhao XX, Daugherty BL, Schwartz B, Maeda S, Pestka S. 1987. Expression of human interferon-alpha-H, an interferon with two potential asparagines-linked glycosylation sites. J Biol Regul Homeost Agents 1(3):103-108.